US-based Hyperion Biosystems and Colorcon on Tuesday declared a licensing agreement to commercialise and market a jointly-developed, anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products.
Colorcon is a supplier of film coating systems, modified release technology, specialty excipients and functional packaging for the healthcare industry. Hyperion Biosystems applies its expertise in optical detection, artificial intelligence (AI) and physics-based algorithms to create solutions for authentication, chemical sensing, product aging, tamper evidence and diagnostics for multiple industries.
On-dose authentication is claimed to integrates security measures directly into the dosage form, providing fast product verification and traceability. When products are separated from their original packaging, taggants applied directly within the film coating provides a convenient way for companies to verify whether a product is authentic in markets around the world.
"This agreement is the result of a multi-year relationship between Hyperion Biosystems and Colorcon," said Jason Cox, PhD, Hyperion Biosystems CEO. "Our teams have closely collaborated to create a unique solution for on-dose authentication. By combining our expertise in authentication additives and our core Halo product suite, we are supporting Colorcon's efforts to solve the highly complex and growing challenge of counterfeit pharmaceutical and nutraceutical products in the global market."
"Colorcon is evaluating various ways to add on-dose authentication technology to its SoteriaRx product portfolio to meet the FDA requirements around physical-chemical identifiers (PCID)," said Gary Pond, Colorcon director of Strategic Business Development. "This agreement with Hyperion Biosystems demonstrates our ongoing commitment to customers by offering innovative solutions that will improve security in the pharmaceutical supply chain, seamlessly integrating into existing manufacturing processes and most importantly, safeguarding both patients and trusted brands."
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals